GO
Loading...

Life Sciences

More

  • MADRID, Sept 28- Merck& Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, also has potential in stomach cancer, new research shows.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system suggest the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • Inovio to start human trials of Ebola vaccine Wednesday, 24 Sep 2014 | 11:28 AM ET

    Sept 24- Vaccine developer Inovio Pharmaceuticals Inc said the company and its partner GeneOne Life Science Inc will start testing its experimental Ebola vaccine in humans in the first half of 2015.. Two other vaccine candidates in development are from GlaxoSmithKline Plc and NewLink Genetics Corp..

  • Record iPhone 6 sales would have been even better Monday, 22 Sep 2014 | 11:04 AM ET
    A customer looks at the new iPhone 6 Plus after it went on sale along with the iPhone 6 at the Apple Omotesando store in Tokyo, Sept. 19, 2014.

    In Monday's The Good, The Bad, and The Ugly: iPhone 6 sales top record; a poll shows attitudes towards corporations; and a German firm shops in U.S.

  • German firm buys American, but not for taxes: CEOs Monday, 22 Sep 2014 | 8:09 AM ET
    The Merck KGaA logo sits outside the company's headquarters in Darmstadt, Germany.

    Merck agrees to acquire Sigma-Aldrich for $17 billion in cash to boost its life science business.

  • PARIS, Sept 18- French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.

  • Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

  • NEW YORK, Sept 11- The highly anticipated debut of Alibaba Group Holding Ltd, the Chinese e-commerce group, will come amid the busiest year for initial public offerings since the technology bubble burst in 2000.. Alibaba's IPO, which could come as soon as Sept. 19, could raise more than $21 billion and claim Facebook Inc's title of biggest tech IPO.

  • Sept 5- Keryx Biopharmaceuticals Inc won U.S. approval for its drug to lower phosphate levels in patients with chronic kidney disease, but the approval included an unexpected safety warning on the label. However, the FDA- mandated label does not include the benefits of the drug in treating anemia.

  • Keryx Biopharma gets U.S. approval for kidney drug Friday, 5 Sep 2014 | 11:28 AM ET

    Sept 5- Keryx Biopharmaceuticals Inc won the U.S. Food and Drug Administration approval for its drug to lower phosphate levels in patients with chronic kidney disease who are already on dialysis. It affects more than 20 million adults in the United States, according to the U.S. Centers for Disease Control and Prevention.

  • Sept 4- NewLink Genetics Corp said the U.S. Food and Drug Administration allowed the company to start testing an experimental Ebola vaccine in humans. The move follows a decision to begin initial human testing of a GlaxoSmithKline vaccine this month and an approval to fast track tests of a Johnson& Johnson vaccine.

  • NewLink says FDA allows human testing of Ebola vaccine Thursday, 4 Sep 2014 | 7:28 AM ET

    Sept 4- NewLink Genetics Corp said the U.S. Food and Drug Administration allowed the company to start testing an experimental Ebola vaccine in humans.

  • PARIS, Sept 3- French drugmaker Sanofi, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 percent in a large final clinical trial. Sanofi has invested more than 1.3 billion euros in the project, undertaking two decades of research on the world's fastest-growing tropical disease.

  • Sept 2- The U.S. Department of Health and Human Services said on Tuesday a federal contract worth up to $42.3 million would help accelerate testing of an experimental Ebola virus treatment that is being developed by privately held Mapp Biopharmaceutical Inc..

  • The success is therefore a "monumental achievement," virologist Thomas Geisbert of the University of Texas Medical Branch wrote in a commentary on the paper, published online in Nature.

  • CHICAGO, Aug 28- Genetic studies of some of the earliest Ebola cases in Sierra Leone reveal more than 300 genetic changes in the virus as it leapt from person to person, changes that could blunt the effectiveness of diagnostic tests and experimental treatments now in development, researchers said on Thursday.

  • LONDON/ NEW YORK, Aug 28- An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build a stockpile of up to 10,000 doses for emergency deployment, if results are good.

  • WINNIPEG, Manitoba, Aug 25- Four monkeys survived the Ebola virus after being injected with a vaccine that included Immunovaccine Inc's technology, the tiny Canadian company said on Monday, and the announcement sent its stock soaring.

  • NEW YORK, Aug 20- An experimental drug from Tekmira Pharmaceuticals Corp helped lab monkeys recover from the most deadly strain of Marburg virus, a close cousin of Ebola, even after symptoms appeared, scientists reported on Wednesday.

  • LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.